AF
CELL

Amalgamated Financial’s PhenomeX Inc. Common Stock CELL Stock Holding History

Amalgamated Financial’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$56K Buy
+7,930
New +$65.6K ﹤0.01% 2382

Other funds holding CELL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Amalgamated Financial's CELL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in PhenomeX Inc. Common Stock (CELL) in Q1 2022: 7,930 shares worth $56K. The stake represents ﹤0.01% of the portfolio and ranks #2382 among its holdings.

130 funds tracked by Wall St. Rank hold CELL as of Q1 2022.

  • Amalgamated Financial held 7,930 shares of PhenomeX Inc. Common Stock worth $56K as of Q1 2022.
  • PhenomeX Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • PhenomeX Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2382 holding.
  • 130 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.